News and Events | www.gliotrain.eu

GLIOTRAIN Represented at the 2018 "Research and Challenges of Brain Conditions in Ireland" Conference

GLIOTRAIN was represented by Programme Manager Dr Alice O'Farrell, PI Dr Brona Murphy and ESR Viktorija Juric at the "Research and Healthcare Responses to the Challenge of Brain Conditions in Ireland" Conference held at the Royal College of Physicians in Ireland on 6th March 2018. The conference, organised jointly by the Irish Brain Council and the Neurological Alliance of Ireland, kicked off #brainawarenessweek. The event focussed on the societal challenges and funding requirements for all brain conditions in Ireland.

Brain Awareness Week 2018

Prof Annette Byrne, GLIOTRAIN Coordinator, has been invited by Brain Tumour Ireland to present in Dublin during Brain Awareness week on March 9th 2018. Prof Byrne's talk will be entitled "Searching for new ways to tackle GBM: Fighting the Good Fight".

GLIOTRAIN Network-wide Training

The first GLIOTRAIN training event will take place at the Royal College of Surgeons in Ireland, Dublin from the 23rd to the 26th April 2018. It will be the first time all ESRs will meet together. There will be an interaction day with all PIs and ESRs to familiarise the students with the programme.

International Conferences

Prof Gabriele Bergers will present at two upcoming international conferences: firstly at the Cancer Research UK Brain Tumour Conference 2018 (in "The tumour microenvironment and the immune system" session and also at the "Brain Tumors Meeting 2018 - From Biology to Therapy" organised by the Nencki Institute of Experimental Biology and Foundation of Clinical and Experimental Oncology offering a talk entitled "Glioma heterogeneity in space and time".

GLIOTRAIN PI delivers a seminar entitled "Cell death control – from mechanisms to applications"

Prof Markus Morrison delivered a seminar entitled "Cell death control – from mechanisms to applications" at the Seminar Series of the Fraunhofer Institute for production technology and automatization, Stuttgart, Germany (January 2018) and "Modelling cancer cell death – from mechanistic insight to systems-based patient prognosis" at the 3rd Open MultiMed Training School (Multi-scale and Multi-level Modelling Methodologies in Biomedicine), Erlangen, Germany, February 2018.

GLIOTRAIN PI delivers two presentations in UK and Austria

Dr Gavin Fullstone presented "Development of Tools for Systems Modelling of Cell Death Signalling" at the Agent-based Modelling User Meeting, Sheffield, UK in October 2017 and "Modelling Apoptotic Signalling Processes using an Agent-based Approach" at the 4th Annual Meeting of the FOR2036 BCL-2 Consortium, Obergurgl, Austria in January 2018.

GLIOTRAIN participates in the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology

GLIOTRAIN participated in the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) held in San Francisco, California in November 2017. Professor Byrne, GLIOTRAIN Coordinator, represented the GLIOTRAIN consortium at the event, meeting with Ms Kathy Oliver of the International Brain Tumour Alliance (IBTA) to discuss GLIOTRAIN’s strategy to address bench to bedside research from the patient’s perspective.

GLIOTRAIN PI Presents at the European Society of Medical Oncology Asia 2017 Congress

Dr Ahmed Idbaih presented at the European Society of Medical Oncology Asia 2017 Congress (Singapore, November 2017) in the session focussed on CNS tumours: Molecular alterations in clinical perspective: From discovery to everyday application in patient management.

GLIOTRAIN PI Presents at the Tumor Niche and Microenvironment workshop

Prof Simone Niclou presented an invited lecture entitled "Tumour-host interactions in Glioblastoma" in the Tumor Niche and Microenvironment workshop at the Journées Cancéropôle Grand Sud-Ouestheld in November 2017, Poitiers.

GLIOTRAIN PI Presents at the Dutch Neuro-oncology working group Meeting

Dr Martine Lamfers gave a talk at the Dutch Working Group Neuro-Oncology in Utrecht (Netherlands) entitled "Drug screening of clinically available anti-cancer agents for the personalized treatment of glioblastoma patients" (September 2017).